Clinician-ordered genomic risk scoring for common cardiometabolic and renal diseases.
Polygenic risk scores, rare pathogenic variants, and family history — integrated into one clinician-ordered report, calibrated across ancestries, for cardiometabolic and renal conditions.
Many people at real disease risk go unflagged by standard risk scores.
Three signals, recalibrated into one number.
A patient isn’t handed three separate scores. ARC-OMIX multiplies each signal against the clinical baseline to produce one recalibrated absolute-risk estimate, the number a clinician actually acts on. Every test includes the polygenic score; ARC-CHOL adds rare-variant classification, and ARC-PREVENT Premium adds family history and absolute risk.
7.5%
Baseline 10-year CHD risk
PCE / PREVENT clinical equation
×
×1.4
Polygenic score
90th percentile, ancestry-calibrated
×
×1.0
Rare variant
None detected; applied only when present
×
×1.2
Family history
First-degree relative with early CHD
=
12.6%
Recalibrated 10-year risk
One number, not three scores
+5.1 points vs the 7.5% baseline (×1.68)
The 7.5% baseline sits at the intermediate-risk boundary; recalibrated, this patient is at 12.6%.
Worked example, illustrative and not a real patient. A 55-year-old at a 7.5% ten-year CHD risk baseline, with a polygenic score at the 90th percentile (×1.4), no rare variant detected (×1.0) and a first-degree relative with early CHD (×1.2): 7.5% × 1.4 × 1.0 × 1.2 = 12.6%. Absolute-risk recalibration and family-history integration are part of ARC-PREVENT Premium, which is coming soon.
Why ARC-OMIX?
Three commitments that run through every test we offer.
Built for your needs
A prevention-focused PRS panel (ARC-PREVENT) for proactive screening, alongside ARC-CHOL — our indication-anchored test for severe hypercholesterolemia — with additional indication-based tests in development.
Ensemble scoring, ancestry-calibrated
Scores are computed with PRSMix, an ensemble method that combines many published polygenic scores into one model per condition. They are calibrated on genotype-derived principal components (measured ancestry, not self-report) projected to a multi-ancestry reference exceeding 100,000 individuals, supporting wide applicability across ancestrally varied populations.
Quality control
Every report will be signed out by the clinical laboratory director. Analytic and clinical validity are documented against defined action thresholds — not presented as certainty where the evidence is provisional.
Conditions Covered
Prevention panel · ARC-PREVENT (coming soon)
Indication-based testing
Separate, single-condition diagnostic tests ordered individually — distinct from the ARC-PREVENT panel above, even where condition names overlap.
Coming soon
Severe Hypercholesterolemia
Not yet available
Coronary Heart Disease
Not yet available
Severe Hypertriglyceridemia
Not yet available
Chronic Kidney Disease
Not yet available
Venous Thromboembolism
Not yet available
Type 2 Diabetes
ARC-OMIX augments your practice.
ARC-PREVENT and ARC-CHOL launch together. Create a free clinician portal account with your NPI now, and you can order the day they launch.
Looking for patient information? Visit our page for patients